Skip to main content
    F

    Fractyl Health, Inc. Common Stock (GUTS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.99
    +0.09 (+9.76%)

    Market Cap: $11.99M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Fractyl Health, Inc. Common Stock (GUTS) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Fractyl Health, Inc. Common Stock are Context Therapeutics (CNTX), Tscan Therapeutics (TCRX) and Citius Pharmaceuticals (CTXR). By market cap, Fractyl Health, Inc. Common Stock ranks 9th of the 13 companies on this page; Transcode Therapeutics (RNAZ) is the largest at $22.35M.

    Peer Comparison

    GUTS's ROIC of -245.8% is below the peer median of -150.1%, and its revenue growth of -57.1% is below the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Fractyl Health, Inc. Common Stock (GUTS)$11.99MN/AN/A0.0%-245.8%-57.1%0.00%
    Context Therapeutics Inc (CNTX)$16.61MN/AN/A0.0%N/A0.0%0.00%
    Tscan Therapeutics Inc (TCRX)$10.89MN/A3.6x0.0%-129.7%-65.8%0.00%
    Citius Pharmaceuticals Inc (CTXR)$14.69MN/A1.9x0.0%-84.3%0.0%0.00%
    Chemomab Therapeutics Ltd DRC (CMMB)$12.31MN/AN/A0.0%N/A0.0%0.00%
    Cyclerion Therapeutics Inc (CYCN)$15.73MN/AN/A0.0%N/A-43.2%0.00%
    Akari Therapeutics PLC (AKTX)$15.54MN/AN/A0.0%N/A0.0%0.00%
    Quantum BioPharma Ltd. (QNTM)$10.35MN/AN/A0.0%-150.1%0.0%0.00%
    Transcode Therapeutics Inc (RNAZ)$22.35MN/AN/A0.0%-412.7%0.0%0.00%
    Phio Pharmaceuticals Corp (PHIO)$9.21MN/AN/A0.0%N/A0.0%0.00%
    Tempest Therapeutics Inc (TPST)$7.64MN/AN/A0.0%-783.6%0.0%0.00%
    Biocardia Inc (BCDA)$12.58MN/AN/A0.0%N/A-100.0%0.00%
    Tvardi Therapeutics, Inc. (TVRD)$15.74MN/AN/A0.0%N/A0.0%0.00%
    Peer median$13.64MN/A2.8x0.0%-150.1%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Fractyl Health, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Context Therapeutics Inc (CNTX)
    Centrexion Therapeutics Corporation, a late-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel, non-opioid...
    CNTX competitors
    Tscan Therapeutics Inc (TCRX)
    Tscan Therapeutics Inc (TCRX) is a pioneering clinical-stage biotechnology company specializing in precision oncology through its proprietary T cell receptor...
    TCRX competitors
    Citius Pharmaceuticals Inc (CTXR)
    Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets critical care products.
    CTXR competitors
    Chemomab Therapeutics Ltd DRC (CMMB)
    Chemomab Therapeutics Ltd. is dedicated to the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases.
    CMMB competitors
    Cyclerion Therapeutics Inc (CYCN)
    Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development...
    Akari Therapeutics PLC (AKTX)
    Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory...
    AKTX competitors
    Quantum BioPharma Ltd. (QNTM)
    Quantum BioPharma Ltd. (QNTM) is an innovative biotechnology company focused on advancing transformative therapies for oncology and autoimmune diseases.
    QNTM competitors
    Transcode Therapeutics Inc (RNAZ)
    TransCode Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development and commercialization of drugs for the treatment of metastatic...
    RNAZ competitors
    Phio Pharmaceuticals Corp (PHIO)
    Phio Pharmaceuticals Corp. The company is headquartered in Marlborough, Massachusetts.
    PHIO competitors
    Tempest Therapeutics Inc (TPST)
    Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated...
    TPST competitors
    Biocardia Inc (BCDA)
    BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapies for cardiovascular disease.
    BCDA competitors
    Tvardi Therapeutics, Inc. (TVRD)
    Tvardi Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company focused on developing novel oncology therapies to meet critical unmet...
    TVRD competitors

    Frequently Asked Questions About GUTS

    Who are Fractyl Health, Inc. Common Stock's main competitors?

    The companies most similar to Fractyl Health, Inc. Common Stock include Context Therapeutics (CNTX), Tscan Therapeutics (TCRX), Citius Pharmaceuticals (CTXR), Chemomab Therapeutics Ltd DRC (CMMB) and Cyclerion Therapeutics (CYCN), listed from the closest match.

    Who is Fractyl Health, Inc. Common Stock's biggest competitor?

    Transcode Therapeutics (RNAZ) is the largest of the similar companies at $22.35M; Context Therapeutics (CNTX) is the closest match by business profile, size, sector and industry.

    How does GUTS stock compare with its competitors?

    GUTS' net margin is 0.0% against a peer median of 0.0%.

    Which of Fractyl Health, Inc. Common Stock's competitors pays a higher dividend?

    Fractyl Health, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Fractyl Health, Inc. Common Stock bigger than its competitors?

    No. Fractyl Health, Inc. Common Stock is 9th by market cap among the 13 companies on this page; the largest is Transcode Therapeutics (RNAZ) at $22.35M.